Astellas

SGN22E (EV-302)

NCT04223856

JCP082

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer (EV-302)

Status:

Recruiting

26459-200.png

III

Phase

Line of Therapy.png

1st+

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

Nectin4

Investigational

Product

Enfortumab Vedotin

Anti-Nectin-4 Antibody-Drug Conjugate (i.v.)

Treatment Arms

o Experimental: Arm A - Enfortumab vedotin + pembrolizumab

o Active Comparator: Arm B - Gemcitabine + cisplatin or carboplatin

o Experimental: Arm C (Not Recruiting) - Enfortumab vedotin + pembrolizumab + Cisplatin or carboplatin